Showing results (341-350 of 447) with videos related to

Sort By:
Pageof 45
Frontiers in Medicine|July 5, 2022
Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative ColitisMaria Gonzalez-Vivo, Minna K Lund Tiirikainen, Montserrat Andreu, et al.
American Journal of Industrial Medicine|November 19, 2009
Occupational health crossing borders part 2: Comparison of 18 occupational health systems across the globeKatja Radon, Vera Ehrenstein, Dennis Nowak, et al.
Cancers|February 25, 2022
Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell LymphomaGrégoire Quinet, Wendy Xolalpa, Diana Reyes-Garau, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2010
CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cellsSven Jähnichen, Christophe Blanchetot, David Maussang, et al.
Archives of General Psychiatry|December 10, 2003
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute maniaMauricio Tohen, Joseph F Goldberg, Ana Maria Gonzalez-Pinto Arrillaga, et al.
The Journal of Biological Chemistry|August 28, 2013
Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivoDavid Maussang, Azra Mujić-Delić, Francis J Descamps, et al.
Plos One|April 13, 2011
Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral moleculesAnna Hultberg, Nigel J Temperton, Valérie Rosseels, et al.
Schizophrenia Bulletin|January 10, 2020
Elevated Extracellular Free-Water in a Multicentric First-Episode Psychosis Sample, Decrease During the First 2 Years of IllnessDaniel Bergé, Anna Mané, Tyler A Lesh, et al.
JTO Clinical and Research Reports|September 25, 2024
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 StudyJoel W Neal, Armando Santoro, Maria Gonzalez-Cao, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 1, 2024
Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysisPablo Cerezuela-Fuentes, Maria Gonzalez-Cao, Teresa Puertolas, et al.
Pageof 45